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OBJECTIVES We investigated whether white-coat hypertension is a risk factor for stroke in relation to silent
cerebral infarct (SCI) in an older Japanese population.
BACKGROUND It remains uncertain whether white-coat hypertension in older subjects is a benign condition
or is associated with an increased risk of stroke.
METHODS We studied the prognosis for stroke in 958 older Japanese subjects (147 normotensives [NT],
236 white-coat hypertensives [WCHT] and 575 sustained hypertensives [SHT]) in whom
ambulatory blood pressure monitoring was performed in the absence of antihypertensive
treatment. In 585 subjects (61%), we also assessed SCI using brain magnetic resonance
imaging.
RESULTS Silent cerebral infarcts were found in 36% of NT (n 5 70), 42% of WCHT (n 5 154), and
53% of SHT (n 5 361); multiple SCIs (the presence of $2 SCIs) were found in 24% of NT,
25% of WCHT and 39% of SHT. During a mean 42-month follow-up period, clinically overt
strokes occurred in 62 subjects (NT: three [2.0%]; WCHT: five [2.1%]; SHT: 54 [9.4%]),
with 14 fatal cases (NT: one [0.7%]; WCHT: 0 [0%]; SHT: 13 [2.3%]). A Cox regression
analysis showed that age (p 5 0.0001) and SHT (relative risk, [RR] [95% confidence interval,
CI]: 4.3 [1.3–14.2], p 5 0.018) were independent stroke predictors, whereas WCHT was not
significant. When we added presence/absence of SCI at baseline into this model, the RR
(95% CI) for SCI was 4.6 (2.0–10.5) (p 5 0.003) and that of SHT was 5.5 (1.8–18.9) versus
WCHT (p 5 0.004) and 3.8 (0.88–16.7) versus NT (p 5 0.07).
CONCLUSIONS In older subjects the incidence of stroke in WCHT is similar to that of NT and one-fourth
the risk in SHT. Although SCI is a strong predictor of stroke, the difference in stroke
prognosis between SHT and WCHT was independent of SCI. It is clinically important to
distinguish WCHT from SHT even after assessment of target organ damage in the elderly.
(J Am Coll Cardiol 2001;38:238–45) © 2001 by the American College of Cardiology
White-coat hypertension (WCHT), defined by persistently
high clinic blood pressure (BP) levels and normal ambula-
tory BP (ABP), is common in clinical practice (1), partic-
ularly in older hypertensive subjects (2), in whom its
frequency may be as high as 40% (3). However, it is still
controversial whether WCHT is a benign condition. In
cross-sectional studies, some authors have found a clustering
of cardiovascular risk factors or increased target organ
damage in WCHT compared with normotensives (NT)
(4–7), whereas others have not (8–13). One way to diag-
nose WCHT is by using ABP monitoring (ABPM) (14).
There are now six published prospective studies using
ABPM to define cardiovascular prognosis (15–21). These
prognostic studies differed widely in design, ranging from a
population study to a study of refractory hypertension. In
most of these studies the subjects were relatively young, and
only one (20) dealt with older subjects with isolated systolic
hypertension. Although all these reports demonstrate that
ABP is a better predictor of cardiovascular prognosis than is
clinic BP, only three of these reports (16,19,21) compared
the event rates in patients with WCHT and those with
sustained hypertension (SHT), whereas the other four
reports estimated the predictive value of ABP after control-
ling for clinic BP in the entire cohort (15,17,18,20).
There are significant racial differences between Japanese
and Caucasians in the demographics of cardiovascular dis-
ease. In Japan, stroke is more common than in Western
countries, whereas coronary artery disease (CAD) is less
common (22). Recently, silent cerebral infarct (SCI) has
often been detected by brain computed tomography or
magnetic resonance imaging (MRI) in older subjects, par-
ticularly in those with hypertension (23–25). Silent cerebral
infarct is the strongest predictor of subsequent clinically
overt stroke (26). The prognosis of WCHT may depend on
the presence or absence of subclinical target organ damage,
and the risk of stroke could be augmented when accompa-
nied by SCI. Furthermore, in older patients with WCHT,
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transient rises of BP might be more likely to trigger
cardiovascular events than in younger patients.
In this study, we investigate whether WCHT is a risk
factor for stroke in relation to SCI in an older Japanese
population.
METHODS
Subjects. This study is based on 958 Japanese subjects,
composed of 811 subjects diagnosed with essential hyper-
tension and 147 NT subjects. This represents 98% of the
973 subjects who were initially enrolled into the study from
six participating institutes (three clinics, two hospitals and
one outpatient clinic of the university hospital) between
January 1, 1992, and January 1, 1998. Hypertensive patients
were selected by the following criteria: 1) essential hyper-
tension with average clinic systolic BP (SBP) $140 mm Hg
and/or average clinic diastolic BP (DBP) of $90 mm Hg
(average for each patient on two or more occasions); 2) age
$50 years. Clinic BP was measured after resting for at least
5 min in the sitting position. No patient had taken any
antihypertensive medication for at least 14 days before the
ABPM study, but 51% had a prior history of antihyperten-
sive medication use (1.4% for the NT group, 34% for the
WCHT group and 58% for the SHT group). Normotensive
subjects (age $50 years) with clinic BPs ,140/90 mm Hg
were volunteers recruited from those enrolled in the annual
health examination and outpatients without symptomatic
medical problems. All of the subjects studied were ambula-
tory and all gave informed consent for the study. We
excluded patients with renal failure (serum creatinine level
$176 mmol/l) or hepatic damage, with obvious present or
past CAD, stroke (including transient ischemic attacks
[TIA]), congestive heart failure or arrhythmia. All the
results of the ABPM and brain MRI were returned to the
physicians who followed up the subjects. All 131 patients
with hypertension reported in our previous cross-sectional
study were included in this study (24). Of the 958 patients,
585 (61%) agreed to and had a brain MRI. There were no
significant differences in the age, gender, body mass index
(BMI) and incidence of cardiovascular disease between
these 585 subjects and the other 373 subjects without brain
MRI examination, whereas the clinic BPs were slightly
higher in the former group than in the latter group (160 vs.
157 mm Hg for systolic, p 5 0.04; 89 vs. 87 mm Hg for
diastolic, p 5 0.03). This study was approved by the
Research Ethics Committee, Department of Cardiology,
Jichi Medical School, Japan.
Diabetes mellitus was defined by a fasting glucose
level $7.8 mmol/l, a random nonfasting glucose level
$11.1 mmol/l, hemoglobin A1c $6.2%, or the use of an
oral hypoglycemic agent or insulin. Hyperlipidemia was
defined by a total cholesterol level $6.2 mmol/l or the use
of an oral lipid-lowering agent. Smokers were defined as
current smokers. Body mass index was calculated as weight
(kg)/height (m)2. Electrocardiographically verified left ven-
tricular hypertrophy (ECG-LVH) was defined as abnor-
mally high voltages of QRS-complexes (R in V5 plus S in V1
$3.5 mV) associated either with flat T waves (,10% of R)
or with ST-segment depression and biphasic T waves.
24-h ABPM. Noninvasive ABPM was carried out on a
weekday with one of three automatic ABPM devices
(ABPM-630, Nippon Colin Co.; TM-2421 or TM-2425,
A and D Co., Japan), which recorded BP and heart rate
every 30 min for 24 h. The accuracy of these devices was
previously validated. The ambulatory data used in the
present study were those obtained by the oscillometric
method. We excluded those who obtained valid BP readings
,80% of either awake attempts or asleep attempts (n 5 66).
Patients who reported in our post-ABPM questionnaire
that their sleep was severely disturbed by wearing the
ABPM were excluded from this study (n 5 53). We used a
cutoff value of 130/80 mm Hg for normal ABP to define
WCHT according to the recommendation of the American
Society of Hypertension (ASH) (27) as follows: clinic BPs
$140/90 mm Hg (either) and 24-h ABPs ,130/80 mm Hg
(both) for WCHT; clinic BPs $140/90 (either) mm Hg
and 24-h ABPs $130/80 mm Hg (either) for SHT.
Brain MRI. Brain MRI was carried out using a supercon-
ducting magnet with a main strength of 1.5 T (MRT200FXII,
Toshiba; SIGNA-Horizon Ver.5.8, General Electric Co. or
Vision, Siemens, Tokyo) within three months of the
ABPM. T1-weighted images and T2-weighted images were
obtained in the transverse plane with 7.8 to 8.0-mm-thick
sections. A SCI was defined as a low signal intensity area
(3 to 15 mm) on T1-weighted images that was also visible
as a hyperintense lesion on T2-weighted images as de-
scribed previously (24,25). Multiple SCI was defined as
$2 SCIs in a person. The MRI images of the subjects were
randomly stored and interpreted by reviewers blind to the
subjects’ names and characteristics. The interclass (non-
SCI 5 0, one SCI 5 1, multiple SCIs 5 2) kappa statistics
were 0.70 and 0.80 for interreader and intrareader, respec-
tively, in our laboratory.
Follow-up and events. The patients’ medical records were
intermittently reviewed since entering the study for drug
therapy and the occurrence of cardiovascular events. The
follow-up evaluation was performed during a 20-month
period from 1996 to 1998; the mean follow-up was 42
Abbreviations and Acronyms
ABPM 5 ambulatory blood pressure monitoring
BMI 5 body mass index
BP 5 blood pressure
MRI 5 magnetic resonance imaging
NT 5 normotension
RR 5 relative risk
SCI 5 silent cerebral infarct
SHT 5 sustained hypertension
WCHT 5 white-coat hypertension
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months, with a range from one to 68 months. When
subjects stopped coming to the clinic, we conducted tele-
phone interviews with them. Events were classified as
cardiac events, stroke events and noncardiovascular deaths.
Stroke events include ischemic stroke (cerebral infarction
and cerebral embolism), hemorrhagic stroke (cerebral hem-
orrhage and subarachnoid hemorrhage) and undefined type
of stroke, but exclude TIA (transient neurological deficits
that disappear within 24 h after the onset). Cardiac events
include fatal and nonfatal acute myocardial infarction
(AMI), unexplained sudden death within 6 h of the abrupt
onset of symptoms, and coronary revascularization. These
events were accepted if documented in the medical records
or if confirmed by the general practitioner. We excluded 17
TIA from the stroke events. Of the total 973 eligible
subjects at baseline, follow-up was obtained in 958 subjects
(98%), and the data analysis was restricted to these subjects.
There was no significant difference among groups in dura-
tion of follow-up.
Statistical analysis. Data are expressed as the mean (stan-
dard deviation, SD). One-way analysis of variance was
performed to detect differences among groups in mean
values, and the x2 test was used to detect differences among
groups in prevalence rates. Survival curves were estimated
using the Kaplan-Meier product-limit method and com-
pared by the Mantel (log-rank) test. Adjusted relative risks
(RR) and 95% confidence intervals were calculated using
Cox regression analysis. For the subjects who experienced
multiple nonfatal cardiovascular events, the analysis in-
cluded only the first stroke event. The above statistics were
performed using SPSS version 8.0J (SPSS Inc., Chicago,
Illinois). Differences with p , 0.05, two-tailed, were con-
sidered statistically significant.
RESULTS
Baseline characteristics. The mean age was significantly
higher in the WCHT and SHT groups than in the NT
group (Table 1). Clinic BP was significantly higher in the
WCHT and SHT groups than in the NT group. The 24-h
SBP of the WCHT group was slightly (3 mm Hg) lower
than that of the NT group, whereas 24-h DBP was not
different between the WCHT and NT groups. ECG-LVH
was more common in the SHT group (19%) than in the NT
or WCHT groups, and tended to be more common in
WCHT than in NT (6.4 vs. 2.7%, p 5 0.15). The
prevalence of SCI was comparable in the WCHT and the
NT groups, whereas it was significantly higher in the SHT
group (Fig. 1). Frequencies of SCI were 39% in previously
untreated WCHT (n 5 91) and 48% (p 5 0.32 vs.
untreated WCHT) in previously treated WCHT (n 5 63);
frequencies were 47% in previously untreated SHT (n 5
138) and 57% (p 5 0.08 vs. untreated SHT) in previously
treated SHT (n 5 223).
Stroke incidence. During the 42-month follow-up period,
62 clinically overt stroke events (40 ischemic strokes, 10
hemorrhagic strokes, 12 unknown subtype) occurred, in-
cluding 14 fatal cases. The incidences of fatal and nonfatal
stroke events were more common than those of fatal and
nonfatal cardiac events (Fig. 2, Table 2). The incidence of
total stroke events and fatal events with WCHT was
comparable to the incidence with NT, but significantly
lower than that with SHT. Marked differences were ob-
served between the SHT and NT groups (p 5 0.003) and
between the SHT and WCHT groups (p 5 0.0003),
whereas there was no difference between WCHT and NT
groups (Fig. 3). Recurrent strokes occurred in two patients,
but for this analysis we ignored recurrent events. In the
Table 1. Baseline Characteristics
Measures
Normotensive Control
Group (n 5 147)
White-Coat Hypertension
Group (n 5 236)
Sustained Hypertension
Group (n 5 575) p Value*
Age, years 68 (9.7) 72 (9.9)† 73 (9.8)† 0.000
Male, % 38 34 40 0.248
Body mass index, kg/m2 23.0 (3.7) 23.8 (3.5) 24.0 (3.5)§ 0.791
Clinic systolic BP, mm Hg 126 (12) 156 (11)†\ 168 (19)† 0.000
Clinic diastolic BP, mm Hg 77 (11) 83 (12)†\ 93 (14)† 0.000
24-h systolic BP, mm Hg 123 (13) 120 (7.7)§\ 146 (13)† 0.000
24-h diastolic BP, mm Hg 70 (7.4) 69 (5.7)\ 82 (8.4)† 0.000
Current smoker, % 21 17 22 0.279
Family history (either parent)
Hypertension, % 16 25§ 27‡ 0.016
Cardiovascular disease, % 14 14¶ 22§ 0.008
Diabetes mellitus (treated), % 8.8 (6.8) 9.7 (8.1) 13 (11) 0.190
Hyperlipidemia (treated), % 23 (20) 21 (16) 18 (13) 0.272
Hematocrit 0.39 (0.06) 0.40 (0.07) 0.40 (0.04) 0.759
Creatinine, mmol/l 79 (22) 79 (21) 80 (19) 0.823
ECG-LVH, % 2.7 6.4# 19‡ 0.000
Duration of follow-up, months 43 (12) 43 (14) 41 (14) 0.065
Data are shown as means (SD) or percentages. *Overall p-values for three-group comparisons of means (ANOVA F-test) or percentages (x2-test); †p , 0.001, ‡p , 0.01, §p
, 0.05 vs. normotensive control group; \p , 0.001, ¶p , 0.01, #p , 0.05 vs. sustained hypertensive group.
BP 5 blood pressure; ECG-LVH 5 left ventricular hypertrophy diagnosed by echocardiography.
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SHT group, one subject had a fatal stroke after an AMI,
two suffered sudden death, and one had an AMI after an
initial stroke during the follow-up period. In the Cox
regression analysis (Table 3), age (RR of 1.8 for a 10-year-
increase, p , 0.0001) and SHT (RR vs. NT 4.3, p 5 0.018,
vs. WCHT 5.6, p 5 0.001) were independent predictors for
stroke, whereas the predictive value of WCHT was not
significantly different from that of NT.
Impact of silent cerebral infarct. When we divided the
585 subjects who had both ABPM and brain MRI into 303
without SCI and 282 with SCI (Fig. 4), strokes occurred in
seven (2.3%) of the former and in 38 (13.5%) of the latter,
indicating that SCI is a strong predictor of clinical stroke
(RR 5 5.9). Strokes occurred in 6.2% of WCHT with SCI,
but in no patients with WCHT but without SCI. To study
the potential mediating role of SCI in explaining the
different stroke prognosis between WCHT and SHT, we
added SCI (0 5 absent, 1 5 present) into the model shown
in Table 3 in the 585 subjects who had a brain MRI (Table
4). The RR of present SCI was 4.6 (p 5 0.003). The RR of
SHT was 5.5 versus WCHT (p 5 0.004) and 3.8 versus NT
(p 5 0.07), whereas that of WHT was comparable to that
of NT.
Impact of antihypertensive treatment. At the time of
follow-up, three (2%) of 147 NT, 76 (32%) of 236 WCHT
and 350 (61%) of 575 SHT were receiving antihypertensive
medications (diuretics, alpha- or beta-blockers, calcium
antagonists or angiotensin-converting enzyme inhibitors).
Strokes occurred in 28 (12.4%) of 225 untreated patients
with SHT and in 26 (7.4%) of 350 treated patients with
Figure 1. Prevalence of silent cerebral infarcts (SCI) detected by brain MRI. Multiple infarcts are defined as $2 infarcts per person. Overall p values for
three groups comparisons are 0.006 for SCIs and 0.002 for multiple SCIs.
Figure 2. Stroke and fatal stroke incidence. Overall p values for three groups comparisons are ,0.0001 for stroke incidence and 0.036 for fatal stroke
incidence.
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SHT; thus the stroke incidence was 40% lower in the
treated group (x2 5 4.0, p 5 0.056). Strokes occurred in
four (2.5%) of 160 untreated patients with WCHT and in
one (1.3%) of 76 treated patients with WCHT; thus the
stroke incidence was 47% lower in the treated group (x2 5
0.35, p 5 0.56).
DISCUSSION
This study has demonstrated that the prevalence of SCI and
the incidence of clinically overt stroke in patients with
strictly defined WCHT are similar to those of NT, and
stroke incidence in both groups was approximately one
quarter of the incidence seen in SHT. It also confirms that
the risk of stroke is strongly predicted by SCI in older
Japanese subjects. When we used daytime BP to distinguish
WCHT from SHT, the results were essentially the same.
In some previous studies that found that WCHT is
associated with increased cardiovascular risk factors or with
advanced target organ damage, the criteria used to define
WCHT have been somewhat loose (4,5). In these studies,
the 24-h or the awake ABP levels of the WCHT patients
were often higher than the corresponding levels in the NT
controls, although still in the “normal” range for that study.
Thus, these studies could not exclude the possibility that
higher ABP levels per se lead to progression of target organ
damage. Furthermore, in the reports without any differences
between 24-h or awake ABP levels between the WCHT
and NT groups, WCHT has not usually been found to be
associated more often with more advanced target organ
damage (ECG-LVH, LV mass index and endothelial cell
dysfunction assessed by plasma von Willebrand factor) than
with the NT group (8–12), although some authors have still
found significant differences (6,7). Accordingly, in this
study we used the relatively strict ABP criteria for defining
WCHT of the ASH (27), which recommended using 24-h
ABP ,130/80 mm Hg. However, the prevalence of
WCHT in our population (29%) was higher than in other
populations (2). This may be due partly to the elderly nature
Figure 3. Stroke-free survival curves.
Table 2. Cardiovascular Prognosis
Measures
Normotensive
Control
Group
(n 5 147)
White-coat
Hypertension
Group
(n 5 236)
Sustained
Hypertension
Group
(n 5 575) p Value*
Nonfatal cardiovascular events
Stroke event, n (%) 3 (2.0) 5 (2.1)§ 54 (9.4)† 0.000
Stroke subtype
Ischemic stroke, n 23 35
Hemorrhagic stroke, n 12 7
Unknown, n 0 12
Cardiac event, n (%) 1 (0.7) 1 (0.4) 10 (1.7) 0.247
Total cardiovascular event, n (%) 4 (2.7) 6 (2.5)§ 60 (10)† 0.000
Fatal events
Stroke death, n (%) 1 (0.7) 0 (0)‡ 13 (2.3) 0.036
Cardiac death, n (%) 1 (0.7) 1 (0.4) 6 (1.0) 0.662
Total cardiovascular death, n (%) 2 (1.4) 1 (0.4)‡ 19 (3.3) 0.032
Noncardiac death, n (%) 4 (2.7) 10 (4.2) 19 (3.3) 0.701
Total death, n (%) 6 (4.1) 11 (4.7) 38 (6.6) 0.358
Data are shown as the number (percentages). *Overall p-values for three-group comparisons by x2-test. †p , 0.01 vs.
normotension control group; ‡p , 0.05, §p , 0.001 vs. sustained hypertension group.
Table 3. Cox Regression Analysis for Stroke (n 5 958)
Covariates
Relative Risk
(95% CI) p Value
Age (10 years) 1.81 (1.36–2.42) 0.000
Male gender* 1.51 (0.91–2.49) 0.109
Body mass index (kg/m2) 0.98 (0.90–1.05) 0.529
Antihypertensive therapy† 0.83 (0.48–1.42) 0.492
Hypertension status‡ 0.000§
White-coat hypertension vs.
normotension
0.76 (0.16–3.45) 0.724
Sustained hypertension vs.
normotension
4.26 (1.28–14.2) 0.018
Sustained hypertension vs. white
coat hypertension
5.58 (2.01–15.5) 0.001
*Female 5 0, male 5 1; †absence 5 0, presence 5 1; ‡normotension: D1 5 1, D2 5
0, D3 5 0; white-coat hypertension: D1 5 0, D2 5 1, D3 5 0; sustained
hypertension: D1 5 0, D2 5 0, D3 5 1; §global test of significance for differences
among three groups.
CI 5 confidence interval.
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of the population and to the fact that 62% were women, the
prevalence of WCHT being higher in women and in the
elderly (2,3).
In our baseline data, SCI was found in 36% of NT, 42%
of WCHT and 53% of SHT, and multiple SCI ($2
SCIs/person) were found in 24% of NT, 25% of WCHT
and 39% of SHT. The prevalence of SCI in elderly
normotensive subjects and elderly hypertensive patients in
this study is similar to what has been reported in previous
studies using brain MRI (41% to 53%) (9,23–25). In this
study, there was no significant difference in the prevalence
of SCI between the NT and WCHT groups, but it was
higher in the SHT group than in either the NT or WCHT
group. This finding is consistent with a previous report in a
different elderly population (9).
The total stroke incidence in the WCHT group (0.61/
100 person-years) was similar to that seen in the NT group
(0.58/100 person-years). Thus, when considered together
with the evidence that there was no difference in the
prevalence of SCI, WCHT seems be no more harmful in
terms of the risk of stroke than NT, even in an older
population. On the other hand, there was a marked differ-
ence in the stroke incidence between the WCHT group
(0.61/100 person-years) and the SHT group (2.7/100
person-years). After adjustment for age, gender, and BMI,
SHT was an independent risk factor, with a RR of stroke of
4.3 in this population, whereas WCHT was unrelated to
stroke. Thus, clinically it is worthwhile to distinguish SHT
from WCHT in the older hypertensive population.
When we studied the effect of SCI on stroke incidence in
the 585 subjects who had both ABPM and brain MRI, we
found that SCI is a strong predictor of clinical stroke (RR 5
5.9). This risk was slightly lower than the RR of approxi-
mately 10 reported in a recent Japanese prospective study of
adults with a mean age of 58 years (26). In the present study,
the few strokes that occurred in the WCHT were all in
those with SCI. Thus, in older WCHT subjects, the stroke
incidence may be definitively determined by SCI. Even
among the SHT, those without any SCI had a lower stroke
incidence than that of the WCHT with SCI. This might
suggest that stroke incidence is determined more powerfully
by the subclinical target organ damage (SCI) than BP levels
per se, especially in the older hypertensives. However,
within the older hypertensive subjects with SCI, the stroke
incidence of WCHT was still lower than that of SHT (36%
of the SHT). Furthermore, when we controlled for the
status of SCI in a Cox regression model, the RR of stroke
associated with a prior SCI was 4.6 (p 5 0.003). The RR of
Figure 4. Stroke incidence in the subjects with silent cerebral infarct (SCI) and in those without any SCI. Overall p value is ,0.0001 for six group
comparisons.
Table 4. Relative Risks for Stroke and Silent Cerebral Infarct
(n 5 585)
Covariates
Relative Risk
(95% CI) p Value
Age (10 years) 1.65 (1.12–2.41) 0.010
Male gender* 1.36 (0.75–2.46) 0.307
Body mass index (kg/m2) 0.98 (0.89–1.07) 0.642
Antihypertensive therapy† 0.57 (0.30–1.07) 0.079
Silent cerebral infarct‡ 4.63 (2.04–10.5) 0.003
Hypertension status§ 0.000\
White-coat hypertension vs.
normotension
0.66 (0.11–4.04) 0.651
Sustained hypertension vs.
normotension
3.82 (0.88–16.7) 0.074
Sustained hypertension vs. white
coat hypertension
5.51 (1.75–18.9) 0.004
*female 5 0, male 5 1; †absence 5 0, presence 5 1; ‡absence 5 0, presence 5 1;
§normotension: D1 5 1, D2 5 0, D3 5 0; white-coat hypertension: D1 5 0, D2 5
1, D3 5 0; sustained hypertension: D1 5 0, D2 5 0, D3 5 1; \global test of
significance for differences among three groups.
CI 5 confidence interval.
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SHT was 5.8 versus WHT (p 5 0.004) and 3.8 versus NT
(p 5 0.07), whereas the RR of WCHT was comparable to
that of NT. Thus, the difference in the stroke prognosis
between SHT and WCHT (or NT) was largely indepen-
dent of SCI status, indicating that identifying the WCHT
versus SHT is prognostically significant even after assess-
ment of SCI.
The overall stroke incidence in this study of older subjects
with a mean age of 72 years was 1.8/100 person-years, five
times higher than the incidence of CAD (0.36/100 person-
years). In Western countries, even in the elderly population,
the incidence of CAD is higher than that of stroke (20,28).
This marked difference in the demographics of cardiovas-
cular disease can be attributed to both racial and cultural
differences between Japanese (or Asians) and Caucasians.
The stroke incidence (0.58/100 person-years) of the NT in
this study was lower, but that of patients with hypertension
(WCHT 1 SHT combined: 2.1/100 person-years) was
higher than that of the elderly (approximately 1/100 person-
years for those $70 years) in the wave-3 population of the
Hisayama Study, a community-based prospective Japanese
study (29). In the Shanghai Trial Of Nifedipine in the
Elderly (30), the stroke incidence in the placebo group of
Asian hypertensive patients was 3.7/100 person-years. Al-
though the mean age of these hypertensive subjects was 66,
which is five years younger than ours, the stroke incidence
was higher than that of our untreated group (2.4/100
person-years). In another recent trial in an elderly Asian
population, the Systolic Hypertension in China (Syst-
China) trial, the stroke incidence of the placebo group
(mean age: 67 years) was 2.08 (31). When we excluded nine
hemorrhagic stroke events from the total 59 stroke events in
811 hypertensive subjects (WCHT 1 SHT), the incidence
of ischemic stroke and unknown subtype was 1.8/100
person-years. This is also lower than the incidence of
thromboembolic stroke (3.4/100 person-years) in the
Japanese-American hypertensive men .65 years from the
Honolulu Heart Program (32). These differences in the
stroke incidence of the Asian population may be due partly
to regional differences in study populations, study design
(community-based or clinic-based) or differences in the
prevalence of treatment.
The frequency of ECG-LVH tended to be higher in the
WCHT group than in the NT group (6.4 vs. 2.7%, p 5
0.15), although the incidence of cardiovascular events was
comparable between the two groups. As LVH carries a
worse prognosis, particularly for cardiac events, this may
involve a worse prognosis for WCHT compared to NT in
Western populations in which cardiac disease is more
common than in the Japanese population.
A limitation of this study is that our NT group consisted
of those who were recruited at the hospital. However, in a
previous study, SCI was detected by brain MRI in 14 of 34
(41%) normotensive healthy Japanese subjects recruited
from a rural Japanese community (23). Thus, the prevalence
(36%) of SCI in our NT group appears slightly less than
that in the community-dwelling elderly Japanese popula-
tion. Other limitations are that there were no BP data
collected at follow-up and that there were differences in the
status of antihypertensive treatment between the WCHT
and SHT groups. At the time of the latest follow-up, 32%
of the former and 61% of the latter were receiving antihy-
pertensive medication. This difference may partly reflect the
impact of our sending the results of the ABPM and brain
MRI to the subjects’ physicians. Stroke incidence was
marginally less common in the treated SHT than in the
untreated SHT (7.4 vs. 12.4%, p 5 0.056), whereas this
difference was not significant in WCHT, because of the low
stroke incidence (1.3 vs. 2.5%, p 5 0.56).
In conclusion, in older Japanese subjects the incidence of
stroke with WCHT is similar to that of NT and one fourth
of the risk with SHT. This pattern persists even after
controlling for the strong predictive effect of SCI on stroke.
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